The triplet gemcitabine (G), epirubicin (E) and docetaxel (Doc) is feasible, safe and highly active as primary systemic therapy (PST) of patients (pts) with multicentric phase I/II trial
| Autor: | Schneeweiss, A., Geberth, M., Krauss, K., Beldermann, F., Wagner, U., von Fournier, D., Hamerla, R., Wallweiner, D., Bastert, G., Huober, J. |
|---|---|
| Zdroj: | In The Breast 2003 12 Supplement 1:S36-S36 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect